Literature DB >> 17908594

Adverse events after intravitreal triamcinolone in patients with and without uveitis.

Anat Galor1, Ron Margolis, Oswaldo M F Brasil, Victor L Perez, Peter K Kaiser, Jonathan E Sears, Careen Y Lowder, Scott D Smith.   

Abstract

PURPOSE: To evaluate the rates of adverse ocular events after intravitreal triamcinolone acetonide (IVTA) injection in patients with and without uveitis.
DESIGN: Retrospective observational case series. PARTICIPANTS: Two hundred twenty-two eyes of 173 patients were included in the study: 45 eyes of 31 patients with macular edema (ME) due to uveitis and 177 eyes of 142 patients with ME secondary to other etiologies.
METHODS: Retrospective review of patients who received IVTA at the Cole Eye Institute for ME attributable to various causes between the years 2001 and 2005. Data review of clinical records included patient demographics, etiology of ME, and adverse outcomes after injection. Rates of adverse outcomes in patients with and without uveitis were compared. MAIN OUTCOME MEASURES: Intraocular pressure (IOP) elevation and posterior subcapsular cataract (PSC) progression.
RESULTS: Uveitis patients were significantly younger, more likely to be female, and more likely to have had prior posterior sub-Tenon's capsule steroid injection and/or glaucoma therapy than their nonuveitis counterparts. In a multivariate analysis adjusting for the differences in these factors, the presence of uveitis was the strongest risk factor for an adverse IOP event (odds ratio, 2.5; 95% confidence interval [CI], 1.0-6.1; P = 0.05). The odds of having a documented increase in PSC after IVTA injection were 5.6 times greater in uveitis eyes (P = 0.007; 95% CI, 1.6-19.6).
CONCLUSIONS: Intraocular pressure elevation and PSC progression occurred with greater frequency in uveitis patients receiving IVTA. Patients with uveitis treated with IVTA should be counseled about these risks and monitored closely.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17908594     DOI: 10.1016/j.ophtha.2007.05.037

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

1.  Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation.

Authors:  Kenan Sonmez; Faruk Ozturk
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

2.  Intravitreal triamcinolone for intraocular inflammation and associated macular edema.

Authors:  Steven M Couch; Sophie J Bakri
Journal:  Clin Ophthalmol       Date:  2009-06-02

3.  Uveitic Macular Edema: Treatment Update.

Authors:  Raquel Goldhardt; Bradley Simon Rosen
Journal:  Curr Ophthalmol Rep       Date:  2016-02-18

4.  Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes.

Authors:  Yoshio Hirano; Takeshi Ito; Miho Nozaki; Tsutomu Yasukawa; Eiji Sakurai; Munenori Yoshida; Yuichiro Ogura
Journal:  Jpn J Ophthalmol       Date:  2009-10-22       Impact factor: 2.447

Review 5.  [Intraocular pressure related to uveitis].

Authors:  U Pleyer; P Ruokonen; C Heinz; A Heiligenhaus
Journal:  Ophthalmologe       Date:  2008-05       Impact factor: 1.059

6.  VESGEN 2D: automated, user-interactive software for quantification and mapping of angiogenic and lymphangiogenic trees and networks.

Authors:  Mary B Vickerman; Patricia A Keith; Terri L McKay; Dan J Gedeon; Michiko Watanabe; Monica Montano; Ganga Karunamuni; Peter K Kaiser; Jonathan E Sears; Quteba Ebrahem; Daniela Ribita; Alan G Hylton; Patricia Parsons-Wingerter
Journal:  Anat Rec (Hoboken)       Date:  2009-03       Impact factor: 2.064

7.  Risk of Cataract in Intermediate Uveitis.

Authors:  Caroline L Minkus; Maxwell Pistilli; Kurt A Dreger; Tonetta D Fitzgerald; Abhishek R Payal; Hosne Begum; R Oktay Kaçmaz; Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum; Grace A Levy-Clarke; H Nida Sen; Eric B Suhler; Jennifer E Thorne; Nirali P Bhatt; C Stephen Foster; Jeanine M Buchanich; John H Kempen
Journal:  Am J Ophthalmol       Date:  2021-03-10       Impact factor: 5.488

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.